BEONTAG
17.1.2023 12:01:56 CET | Business Wire | Press release
Today, Beontag – one of the world’s largest manufacturers of self-adhesives and smart tags (such as digital labels, and labeling technology solutions like RFID and NFC) – announced that Tags Lux Sarl., a wholly owned subsidiary of the Company, has secured and closed a binding agreement for a syndicated loan of €120 million with global banks and Deutsche Bank as sole lead arranger.
Beontag, the second largest provider of digital RFID and NFC solutions for some of the world’s biggest fashion and consumer brands, is expected to achieve €550 Million in revenue for 2022, with international and national acquisitions, integrations and expansion contributing to significant top-line growth from pro forma actualized revenues of more than €400 Million in 2021. This is the first significant, international capital raise by the Brazilian-founded company – with operations now spanning more than 15 international facilities and a presence in over 40 countries.
Terms of Syndicated Facility
- The syndicated loan shall mature within 60 months from closing date with 18 months grace period, including a possibility of prepayment from the 18th month.
- Beontag intends to use the net proceeds from the issuance to primarily refinance its existing debt throughout the group. Any excess proceeds will be used to support organic strategic initiatives across multiple geographies and enhance liquidity.
- The transaction is expected to be leverage-neutral after closing.
- The loan shall carry an interest rate of EURIBOR plus 4.5% per annum and contains incentivised terms that are linked to Beontag 2030 ESG strategy, which is aligned to the United Nations Sustainable Development Goals (SDGs). Every year, Beontag will seek third-party verification to certify and report upon progress against the ESG-related terms agreed.
Global Expansion, Borderless Solutions
Beontag’s Chief Financial Officer, Pedro Christ, commented: “Investment is a key aspect of our journey to become a truly borderless, end-to-end solutions provider of self-adhesive label stock and IoT solutions. And we believe this syndicated capital raise is a good example of the confidence of international investors in Beontag’s global strategy, as well as our current operational fundamentals.
For 2023, and beyond, we are excited to continue to innovate and expand our solutions to meet our clients’ demands for future-focused support, all while taking care to improve our ESG credentials and reduce the impact of our sector on the planet.”
The Managing Director of Global Emerging Markets from Deutsche Bank, Ricardo Cunha, added: “We are delighted to partner with Beontag for this transaction. This commitment, with and added ESG incentive, reflects our confidence in both the strength and sustainable intention of their innovative plans for the sector.
We look forward to keep supporting Beontag as the company expands into different markets and geographies.”
ENDS
ABOUT BEONTAG
For more than 40 years, Beontag has been dedicated to developing the future of pressure sensitive label stock and RFID technology, being world leaders in both segments. Today the company’s dedicated team, leading technology, global reach, and capabilities help the world work more efficiently, reliably, and safely. Beontag´s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill Beontag´s mission to be a digital enabler.
With modern manufacturing facilities, permanent investment and a highly qualified team, the company has been expanding its business globally and is one of the largest and most respected self-adhesive companies in Latin America. It also operates in the technology sector and has a wide portfolio of Internet of Things (IoT) solutions, focused on the manufacture of radiofrequency smart labels, as well as on the development of software for the integration of the logistics chain, traceability, and product authentication.
To learn more, visit: https://beontag.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom